News & Media

Press Releases

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism Download a PDF copy of this press release: EN FR Lyon, …

Download a PDF: EN or FR

Amolyt Pharma Announces Research Collaboration with PeptiDream

Amolyt Pharma Announces Research Collaboration with PeptiDream Download a PDF copy of this press release: EN FR Amolyt and Peptidream will collaborate to optimize and …

Download a PDF: EN or FR

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed.

Download a PDF: EN or FR

Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced the appointment of Pierre Legault, MBA, CPA as director and chairman of its board of directors…

Download a PDF: EN or FR

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and Metabolic Diseases

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and …

Download a PDF: EN or FR

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

Amolyt Pharma 3 announces that it has completed a €67 million Series A financing round …

Download a PDF: EN or FR

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

Announces a key addition to its leadership team and the structuring of its product portfolio in line with its ambition to become a leading global rare disease company …

Download a PDF: EN or FR

Upcoming events

Date: January 11-14, 2021
Location: Virtual

Date: January 21, 2021
Location: Virtual

Learn more about the meeting »

Date: February 28, 2021

Learn more about the event »

Date: March 20-23, 2021

Learn more about the conference »

Social Updates

TWITTER

Scroll to Top